Skip to main navigation
Instil Bio logo
  • Home
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR

News Releases

November 13, 2024
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
September 16, 2024
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
August 13, 2024
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 1, 2024
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
May 10, 2024
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
March 21, 2024
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
January 16, 2024
Instil Bio Announces Strategic Update

Investor Tools

Instil Bio Instil Bio

Footer Menu

  • About
  • Careers
  • Pipeline
  • Contact Us
  • Publications

Site Social Media Links

  • LinkedIn LinkedIn
  • Twitter Twitter
© 2024 Instil Bio. All Rights Reserved
Privacy Policy Terms of Service Agency Policy